CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Adenocarcinoma
- Bile Duct Cancer
- Biliary Tract Cancer
- Bladder Cancer
- HER2 Positive Breast Cancer
- HER2 Positive Gastric Cancer
- Lung Cancer - Non Small Cell
- Ovarian Neoplasms
- Breast Cancer
- Breast Neoplasm
- Cancer
- Colorectal Cancer
- HER-2 Gene Amplification
- Carcinoma, Squamous
- Carcinoma, Ductal
- Esophagogastric Junction Neoplasms
- Lung Cancer, Small Cell
- Prostate Cancer
- Stomach Neoplasms
- Inflammatory Breast Cancer
- Carcinoma, Hepatocellular
- Carcinoma Transitional Cell
- Malignant Neoplasms
- Carcinoma, Ovarian Epithelial
- HER-2 Protein Overexpression
- HER2 Positive Solid Tumors
- Endometrial Cancer
- HER2 Positive
- Pancreatic Cancer
- Carcinoma, Small Cell
- Head and Neck Cancer
- Type
- Interventional
- Phase
- Phase 1
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
A Phase 1, First in Human Study of Adenovirally Transduced Autologous Macrophages Engineered to Contain an Anti-HER2 Chimeric Antigen Receptor in Subjects with HER2 Overexpressing Solid Tumors
A Phase 1, First in Human Study of Adenovirally Transduced Autologous Macrophages Engineered to Contain an Anti-HER2 Chimeric Antigen Receptor in Subjects with HER2 Overexpressing Solid Tumors
Tracking Information
- NCT #
- NCT04660929
- Collaborators
- Not Provided
- Investigators
- Study Director: Debora Barton, MD Carisma Therapeutics
Get Well Soon